The Asean Pharmaceutical Manufacturing Industry Is Expected To Grow By 12.8 Percent Annually With A Total Addressable Market Cap Of $148.3 Billion Between 2022-2027, Driven By The Increasing Prevalence Of Chronic Ailments, Growing Geriatric Population, High Investment In Research And Development, And Rising Per Capita Healthcare Expenditure Amid The Covid-19 Pandemic.
Universal Health Coverage And The Sustainable Development Goal (Sdg) For Health Will Be Achieved In South-East Asia Region Only If There Is A Significant Improvement In Access To Medicines. Many Interventions Contribute To Improving Access To Drugs, Including Measures That Address The Delivery, Governance (Policy, Regulation, Monitoring, And Others) And Financing Of Medicines.
Regulation And Quality Assurance Are Essential Aspects Of Access And Increasing Attention Is Being Given To The Regulation Of Drugs In The South-East Asia Region. Established To Bring The World’s Foremost Medical Innovations To Asia In The Different Fields Of Medicine Is Medicell Pharmaceutical. Medicell's Product Lines Have Expanded From Pharmaceuticals To Cosmetics, Health Supplements, And Medical Devices Since Its Foundation.
Its Sales Channel Has Grown And Expanded Both Horizontally And Vertically. To Satisfy The Increasing Needs To Meet Drug-Storage Conditions, Medicell Has Expanded Its Warehouse Capabilities In Size, Quantity, And Quality. “Our Sales & Marketing Team Has Evolved From Traditional Brick-And-Mortar Sales To Include An Online E-Commerce Platform, Known As Medimart.
Our Regulatory And Procurement Teams Have Emerged Professionally Both In Strength And Knowledge To Meet Ever-Growing Demands From Health Authorities”, Says Ho See Chek, Founder & Ceo.
The Growth Factor
Between 2009 And 2017, The Proportion Of Older Persons With Chronic Conditions Nearly Doubled. The Most Common And Fastest-Growing Medical Diseases Today In 2023 And In The Foreseeable Future Are Hyperlipidemia, Hypertension, `And Diabetes. The Need For Pharmaceuticals To Treat Various Medical Disorders Is Increasing At An Exponential Rate, And Medicell Pharmaceutical Is Well Positioned To Provide These Drugs To The Market. “Our Key Differentiating Factor From The Competitors Is Our Continuous Commitment To Our Partners’ Success Through An Integrated Ecosystem Of Established Distribution Channels, Up-To-Date Market And Regulatory Know-How, A Strong And Dedicated Professional Team And Strong Governance Around Financial Management. This Leads To Long-Term Trust Being Built Between Medicell Pharmaceutical And Our Partners”, Prides Ho See Chek.
Asean, A Grouping Of Ten South-East Asian Countries With A Combined Population Of More Than 600 Million People, Is An Important Region Within Asia. With A Vast And Rapidly Growing Population And Rising Purchasing Power, There Is Enormous Growth Potential Within The Region. Medicell's Road Map Includes Asean Regionalization, Expanding Our Product Mix (For Both Innovator And Generic Drugs), And Elevating The Company’s Global Partner Networks For Drug Procurement.
Driving Through A Customer-Centric Culture
Medicell Pharmaceutical Continuously Strives To Achieve High Standard Of Product Quality And Service Excellency. Our Enterprise Upholds A Competitive Edge In The International Market Through Fair Pricing Strategies, Timely Deliveries, And An Expanding Network Of Global Partners. In Line With Our Growth And Development Strategies, Medicell Actively Pursues New Technologies And Information Systems That Can Help Carry The Company To The Next Level Of Business Performance. Medicell Stays True To Our Dedication And Commitment To Meeting The Customer's Needs And Augmenting Our Business Through The Customer-Centric Practices.
Established To Bring The World's Foremost Medical Innovations To Asia Is Medicell Pharmaceutical
Medicell Is Devoted To The Success Of Our Partners Through Our Proven Engagement Strategy And Increasing Market Penetration By Continuously Discovering Appropriate Pharmaceutical Drugs And Perform The Necessary Regulatory- Related Due Diligence To Ensure Successful Product Registration With Health Authorities. By Providing An Efficient Distribution, Logistics, And Warehousing Channel For Product Storage And Delivery, We Assist Our Partners In Product Localization Adaptation To Market Conditions And Expectations.
Ho See Chek, Founder & CEO, Medicell Pharmaceutical
Exercising In Pharmaceutical Industry For More Than 30 Years, See Chek Has Always Been Very Passionate About The Medical Institutions. Through Years Of Experience, He Has Single-Handedly Built Medicell Pharmaceutical As One Of The Leading Pharmaceutical Marketing And Distribution Companies In Asia With A Well-Established Partners’ Network Globally, Together With Strong Ties To The Medical Industry.